Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe

  Malignant Lymphoma

  Free Subscription

Articles published in Leukemia

Retrieve available abstracts of 97 articles:
HTML format

Single Articles

    May 2020
  1. DRIESSEN J, Visser O, Zijlstra JM, Lugtenburg PJ, et al
    Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.
    Leukemia. 2020 May 28. pii: 10.1038/s41375-020-0875.
    PubMed     Abstract available

  2. REUTTER K, Sandmann S, Rohde J, Muller S, et al
    Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma.
    Leukemia. 2020 May 14. pii: 10.1038/s41375-020-0862.

    Good prognosis or poor prognosis, dose-intensive or less intensive: who decides for adults with T-lymphoblastic lymphoma/leukemia.
    Leukemia. 2020 May 12. pii: 10.1038/s41375-020-0861.

  4. ATTARBASCHI A, Carraro E, Ronceray L, Andres M, et al
    Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents.
    Leukemia. 2020 May 11. pii: 10.1038/s41375-020-0841.
    PubMed     Abstract available

  5. WULF GG, Altmann B, Ziepert M, D'Amore F, et al
    Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
    Leukemia. 2020 May 7. pii: 10.1038/s41375-020-0838.
    PubMed     Abstract available

    April 2020
  6. NAKAMURA K, Casey M, Oey H, Vari F, et al
    Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
    Leukemia. 2020 Apr 8. pii: 10.1038/s41375-020-0811.
    PubMed     Abstract available

    March 2020
  7. CHEN Q, Feng J, Wu J, Yu Z, et al
    HKDC1 C-terminal based peptides inhibit extranodal natural killer/T-cell lymphoma by modulation of mitochondrial function and EBV suppression.
    Leukemia. 2020 Mar 23. pii: 10.1038/s41375-020-0801.
    PubMed     Abstract available

  8. HUSBY S, Favero F, Nielsen C, Sorensen BS, et al
    Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study.
    Leukemia. 2020 Mar 20. pii: 10.1038/s41375-020-0795.
    PubMed     Abstract available

  9. KREUTMAIR S, Klingeberg C, Poggio T, Andrieux G, et al
    Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model.
    Leukemia. 2020 Mar 17. pii: 10.1038/s41375-020-0789.
    PubMed     Abstract available

  10. DI M, Ollila TA, Olszewski AJ
    Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study.
    Leukemia. 2020 Mar 17. pii: 10.1038/s41375-020-0798.

  11. CHEN SY, Yang Y, Qi SN, Wang Y, et al
    Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making.
    Leukemia. 2020 Mar 9. pii: 10.1038/s41375-020-0791.
    PubMed     Abstract available

  12. FRAGLIASSO V, Verma A, Manzotti G, Tameni A, et al
    The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK(-) anaplastic large cell lymphoma by regulating the DNA helicase HELLS.
    Leukemia. 2020 Mar 2. pii: 10.1038/s41375-020-0754.
    PubMed     Abstract available

    February 2020
  13. KAWASHIMA M, Carreras J, Higuchi H, Kotaki R, et al
    PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
    Leukemia. 2020 Feb 24. pii: 10.1038/s41375-020-0737.
    PubMed     Abstract available

  14. TIAN XP, Xie D, Huang WJ, Ma SY, et al
    A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study.
    Leukemia. 2020 Feb 20. pii: 10.1038/s41375-020-0757.
    PubMed     Abstract available

  15. HONG H, Li Y, Lim ST, Liang C, et al
    A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group.
    Leukemia. 2020 Feb 17. pii: 10.1038/s41375-020-0740.

  16. LENZ G, Hawkes E, Verhoef G, Haioun C, et al
    Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
    Leukemia. 2020 Feb 14. pii: 10.1038/s41375-020-0743.
    PubMed     Abstract available

  17. SONG JY, Egan C, Bouska AC, Zhang W, et al
    Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma.
    Leukemia. 2020 Feb 13. pii: 10.1038/s41375-020-0739.

    December 2019
  18. PICHARD A, Marcatili S, Karam J, Constanzo J, et al
    The therapeutic effectiveness of (177)Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest.
    Leukemia. 2019 Dec 13. pii: 10.1038/s41375-019-0677.
    PubMed     Abstract available

  19. RULE SA, Cartron G, Fegan C, Morschhauser F, et al
    Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
    Leukemia. 2019 Dec 11. pii: 10.1038/s41375-019-0658.

    November 2019
  20. JIN X, Shi Q, Li Q, Zhou L, et al
    CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-kappaB signaling.
    Leukemia. 2019 Nov 27. pii: 10.1038/s41375-019-0661.
    PubMed     Abstract available

  21. RAVI D, Sarkar S, Purvey S, Passero F, et al
    Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
    Leukemia. 2019 Nov 26. pii: 10.1038/s41375-019-0663.
    PubMed     Abstract available

  22. HARRINGTON CT, Sotillo E, Robert A, Hayer KE, et al
    Correction: Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.
    Leukemia. 2019 Nov 22. pii: 10.1038/s41375-019-0650.
    PubMed     Abstract available

  23. GEHRINGER F, Weissinger SE, Moller P, Wirth T, et al
    Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma.
    Leukemia. 2019 Nov 12. pii: 10.1038/s41375-019-0628.
    PubMed     Abstract available

  24. KAMIJO H, Miyagaki T, Takahashi-Shishido N, Nakajima R, et al
    Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.
    Leukemia. 2019 Nov 11. pii: 10.1038/s41375-019-0622.
    PubMed     Abstract available

  25. RIABINSKA A, Lehrmann D, Jachimowicz RD, Knittel G, et al
    ATM activity in T cells is critical for immune surveillance of lymphoma in vivo.
    Leukemia. 2019 Nov 5. pii: 10.1038/s41375-019-0618.
    PubMed     Abstract available

  26. MOHTY M, Gautier J, Malard F, Aljurf M, et al
    CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
    Leukemia. 2019 Nov 5. pii: 10.1038/s41375-019-0615.
    PubMed     Abstract available

    October 2019
  27. YOUNG KH
    Hematopoietic stem cell transplantation for adults with T-cell lymphoblastic lymphoma: can we successfully step into the era of precision medicine?
    Leukemia. 2019 Oct 22. pii: 10.1038/s41375-019-0608.

  28. ADAMS CM, Mitra R, Vogel AN, Liu J, et al
    Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma.
    Leukemia. 2019 Oct 21. pii: 10.1038/s41375-019-0611.

  29. EICHENAUER DA, Plutschow A, Fuchs M, Hartmann S, et al
    Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group.
    Leukemia. 2019 Oct 21. pii: 10.1038/s41375-019-0609.

  30. JIANG D, Tian X, Bian X, Zhu T, et al
    T cells redirected against Igbeta for the immunotherapy of B cell lymphoma.
    Leukemia. 2019 Oct 17. pii: 10.1038/s41375-019-0607.
    PubMed     Abstract available

    September 2019
  31. WANG M, Rule S, Zinzani PL, Goy A, et al
    Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
    Leukemia. 2019 Sep 26. pii: 10.1038/s41375-019-0575.

  32. STAIGER AM, Altenbuchinger M, Ziepert M, Kohler C, et al
    A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.
    Leukemia. 2019 Sep 17. pii: 10.1038/s41375-019-0573.
    PubMed     Abstract available

  33. SONG Y, Gao Q, Zhang H, Fan L, et al
    Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
    Leukemia. 2019 Sep 13. pii: 10.1038/s41375-019-0545.
    PubMed     Abstract available

  34. SCHEIJEN B, Meijers RWJ, Rijntjes J, van der Klift MY, et al
    Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS.
    Leukemia. 2019;33:2227-2240.
    PubMed     Abstract available

    August 2019
  35. DESCH AK, Hartung K, Botzen A, Brobeil A, et al
    Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma.
    Leukemia. 2019 Aug 20. pii: 10.1038/s41375-019-0541.
    PubMed     Abstract available

  36. SUN Y, Ding N, Song Y, Yang Z, et al
    Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.
    Leukemia. 2019;33:2105-2110.

  37. RACK KA, van den Berg E, Haferlach C, Beverloo HB, et al
    European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.
    Leukemia. 2019;33:1851-1867.
    PubMed     Abstract available

    July 2019
  38. KATAOKA K, Miyoshi H, Sakata S, Dobashi A, et al
    Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Leukemia. 2019;33:1687-1699.
    PubMed     Abstract available

  39. LEE G, Ryu HJ, Choi JW, Kang H, et al
    Characteristic gene alterations in primary gastrointestinal T- and NK-cell lymphomas.
    Leukemia. 2019;33:1797-1832.

    June 2019
  40. VRZALIKOVA K, Ibrahim M, Vockerodt M, Perry T, et al
    Correction: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells.
    Leukemia. 2019 Jun 25. pii: 10.1038/s41375-019-0511.
    PubMed     Abstract available

  41. ALKODSI A, Cervera A, Zhang K, Louhimo R, et al
    Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.
    Leukemia. 2019 Jun 11. pii: 10.1038/s41375-019-0509.
    PubMed     Abstract available

    May 2019
  42. NAM J, Kim DU, Kim E, Kwak B, et al
    Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.
    Leukemia. 2019 May 28. pii: 10.1038/s41375-019-0492.
    PubMed     Abstract available

  43. ZHU F, Guo H, Bates PD, Zhang S, et al
    PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
    Leukemia. 2019 May 23. pii: 10.1038/s41375-019-0489.
    PubMed     Abstract available

  44. JAIN T, Sauter CS, Shah GL, Maloy MA, et al
    Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.
    Leukemia. 2019 May 21. pii: 10.1038/s41375-019-0476.

  45. LUPINO L, Perry T, Margielewska S, Hollows R, et al
    Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma.
    Leukemia. 2019 May 16. pii: 10.1038/s41375-019-0478.
    PubMed     Abstract available

  46. WATATANI Y, Sato Y, Miyoshi H, Sakamoto K, et al
    Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.
    Leukemia. 2019 May 15. pii: 10.1038/s41375-019-0473.
    PubMed     Abstract available

  47. STILGENBAUER S, Aurran Schleinitz T, Eichhorst B, Lang F, et al
    Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.
    Leukemia. 2019 May 14. pii: 10.1038/s41375-019-0475.

  48. CRISTOFOLETTI C, Bresin A, Picozza M, Picchio MC, et al
    Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.
    Leukemia. 2019;33:1231-1242.
    PubMed     Abstract available

  49. TORREY H, Khodadoust M, Tran L, Baum D, et al
    Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sezary syndrome.
    Leukemia. 2019;33:1206-1218.
    PubMed     Abstract available

    April 2019
  50. TIAN XP, Huang WJ, Huang HQ, Liu YH, et al
    Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.
    Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0466.
    PubMed     Abstract available

  51. PAPIN A, Tessoulin B, Bellanger C, Moreau A, et al
    CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
    Leukemia. 2019 Apr 2. pii: 10.1038/s41375-019-0463.
    PubMed     Abstract available

    March 2019
  52. HARRINGTON CT, Sotillo E, Robert A, Hayer KE, et al
    Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.
    Leukemia. 2019 Mar 26. pii: 10.1038/s41375-019-0454.
    PubMed     Abstract available

  53. ARAF S, Wang J, Korfi K, Pangault C, et al
    Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.
    Leukemia. 2019 Mar 23. pii: 10.1038/s41375-019-0425.
    PubMed     Abstract available

  54. SASI BK, Martines C, Xerxa E, Porro F, et al
    Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
    Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0442.
    PubMed     Abstract available

  55. NGUYEN PH, Niesen E, Hallek M
    New roles for B cell receptor associated kinases: when the B cell is not the target.
    Leukemia. 2019;33:576-587.
    PubMed     Abstract available

    January 2019
  56. VEKARIA PH, Kumar A, Subramaniam D, Dunavin N, et al
    Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.
    Leukemia. 2019 Jan 21. pii: 10.1038/s41375-018-0355.
    PubMed     Abstract available

  57. DODERO A, Guidetti A, Tucci A, Barretta F, et al
    Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.
    Leukemia. 2019 Jan 10. pii: 10.1038/s41375-018-0320.

  58. THURNER L, Hartmann S, Fadle N, Kemele M, et al
    LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.
    Leukemia. 2019;33:148-158.
    PubMed     Abstract available

  59. ANASTASIADOU E, Stroopinsky D, Alimperti S, Jiao AL, et al
    Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Leukemia. 2019;33:132-147.
    PubMed     Abstract available

    December 2018
  60. EDGINTON-WHITE B, Cauchy P, Assi SA, Hartmann S, et al
    Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0311.
    PubMed     Abstract available

  61. PENG RJ, Han BW, Cai QQ, Zuo XY, et al
    Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0324.
    PubMed     Abstract available

    October 2018
  62. FRASER G, Cramer P, Demirkan F, Silva RS, et al
    Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0276.
    PubMed     Abstract available

  63. HOUOT R, Cartron G, Bijou F, de Guibert S, et al
    Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0282.

    August 2018
  64. PRUTSCH N, Gurnhofer E, Suske T, Liang HC, et al
    Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
    Leukemia. 2018 Aug 21. pii: 10.1038/s41375-018-0239.
    PubMed     Abstract available

  65. BORCHMANN S, Muller H, Haverkamp H, Baues C, et al
    Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG).
    Leukemia. 2018 Aug 21. pii: 10.1038/s41375-018-0240.
    PubMed     Abstract available

    April 2018
  66. HU T, Wu Q, Chong Y, Qin H, et al
    FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
    PubMed     Abstract available

    March 2018
  67. SCHLEUSSNER N, Merkel O, Costanza M, Liang HC, et al
    The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
    Leukemia. 2018 Mar 28. pii: 10.1038/s41375-018-0045.
    PubMed     Abstract available

  68. SUN W, Malvar J, Sposto R, Verma A, et al
    Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
    Leukemia. 2018 Mar 15. pii: 10.1038/s41375-018-0094.
    PubMed     Abstract available

    February 2018
  69. GALLARDO F, Bertran J, Lopez-Arribillaga E, Gonzalez J, et al
    Novel phosphorylated TAK1 species with functional impact on NF-kappaB and beta-catenin signaling in human Cutaneous T-cell lymphoma.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0066.
    PubMed     Abstract available

  70. ARAF S, Wang J, Korfi K, Pangault C, et al
    Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.
    Leukemia. 2018 Feb 8. pii: 10.1038/s41375-018-0043.

  71. NAIRISMAGI M-, Gerritsen ME, Li ZM, Wijaya GC, et al
    Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0004.
    PubMed     Abstract available

  72. RULE S, Jurczak W, Jerkeman M, Rusconi C, et al
    Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0023.

  73. KLYMENKO T, Bloehdorn J, Bahlo J, Robrecht S, et al
    Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
    Leukemia. 2018;32:364-375.
    PubMed     Abstract available

  74. LIU E, Tong Y, Dotti G, Shaim H, et al
    Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Leukemia. 2018;32:520-531.
    PubMed     Abstract available

    November 2017
  75. HARTMANN K, Illing A, Leithauser F, Baisantry A, et al
    Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice.
    Leukemia. 2017 Nov 10. doi: 10.1038/leu.2017.
    PubMed     Abstract available

  76. GERMINI D, Tsfasman T, Klibi M, El-Amine R, et al
    HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells.
    Leukemia. 2017;31:2515-2522.
    PubMed     Abstract available

    October 2017
  77. HU G, Dasari S, Asmann YW, Greipp PT, et al
    Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.
    Leukemia. 2017 Oct 13. doi: 10.1038/leu.2017.
    PubMed     Abstract available

  78. SOMMERMEYER D, Hill T, Shamah SM, Salter AI, et al
    Fully human CD19-specific chimeric antigen receptors for T-cell therapy.
    Leukemia. 2017;31:2191-2199.
    PubMed     Abstract available

  79. CHEN KH, Wada M, Pinz KG, Liu H, et al
    Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Leukemia. 2017;31:2151-2160.
    PubMed     Abstract available

    September 2017
  80. JIA YJ, Liu ZB, Wang WG, Sun CB, et al
    HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
    Leukemia. 2017 Sep 28. doi: 10.1038/leu.2017.
    PubMed     Abstract available

  81. VRZALIKOVA K, Ibrahim M, Vockerodt M, Perry T, et al
    S1PR1 drives a feed forward signalling loop to regulate BATF3 and the transcriptional programme of hodgkin lymphoma cells.
    Leukemia. 2017 Sep 7. doi: 10.1038/leu.2017.
    PubMed     Abstract available

    August 2017
  82. FUJISAWA M, Sakata-Yanagimoto M, Nishizawa S, Komori D, et al
    Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.
    Leukemia. 2017 Aug 23. doi: 10.1038/leu.2017.
    PubMed     Abstract available

  83. ZAMO A, Pischimarov J, Schlesner M, Rosenstiel P, et al
    Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole exome sequencing.
    Leukemia. 2017 Aug 21. doi: 10.1038/leu.2017.
    PubMed     Abstract available

  84. KARUBE K, Enjuanes A, Dlouhy I, Jares P, et al
    Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Abstract available

    July 2017
  85. CHEADLE EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, et al
    A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Abstract available

  86. YAO Z, Deng L, Xu-Monette ZY, Manyam GC, et al
    Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
    Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.
    PubMed     Abstract available

  87. JAIN N, Zhu H, Khashab T, Ye Q, et al
    Targeting nucleolin for better survival in diffuse large B-cell lymphoma.
    Leukemia. 2017 Jul 10. doi: 10.1038/leu.2017.
    PubMed     Abstract available

    June 2017
  88. SUN B, Fiskus W, Qian Y, Rajapakshe K, et al
    BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
    Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.
    PubMed     Abstract available

  89. LOLLIES A, Hartmann S, Schneider M, Bracht T, et al
    An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
    Leukemia. 2017 Jun 29. doi: 10.1038/leu.2017.
    PubMed     Abstract available

    May 2017
  90. KASENDA B, Ihorst G, Schroers R, Korfel A, et al
    High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma-a prospective multicentre trial by the German cooperative PCNSL study group.
    Leukemia. 2017 May 31. doi: 10.1038/leu.2017.
    PubMed     Abstract available

    April 2017
  91. VAN DER MEULEN M, Dinmohamed AG, Visser O, Doorduijn JK, et al
    Improved survival in primary central nervous system lymphoma up to age 70 only: A population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015.
    Leukemia. 2017 Apr 28. doi: 10.1038/leu.2017.
    PubMed     Abstract available

    March 2017
  92. ATSAVES V, Tsesmetzis N, Chioureas D, Kis L, et al
    PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large cell lymphoma.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Abstract available

  93. DZIKIEWICZ-KRAWCZYK A, Kok K, Slezak-Prochazka I, Robertus JL, et al
    ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma.
    Leukemia. 2017 Mar 23. doi: 10.1038/leu.2017.
    PubMed     Abstract available

    January 2017
  94. MONJEZI R, Miskey C, Gogishvili T, Schleef M, et al
    Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
    Leukemia. 2017;31:186-194.
    PubMed     Abstract available

  95. RUELLA M, Kenderian SS, Shestova O, Klichinsky M, et al
    Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.
    Leukemia. 2017;31:246-248.

    March 2016
  96. GONDEK LP, Zheng G, Ghiaur G, DeZern AE, et al
    Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.
    Leukemia. 2016 Mar 15. doi: 10.1038/leu.2016.
    PubMed     Abstract available

    February 2016
  97. MIRANDA MB, Lauseker M, Kraus MP, Proetel U, et al
    Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment- long-term observation in CML Study IV.
    Leukemia. 2016 Feb 9. doi: 10.1038/leu.2016.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.